Overview

Dr. Paul Harch, a pioneer in hyperbaric medicine, presents compelling evidence on using Hyperbaric Oxygen Therapy (HBOT)
to slow—and even reverse—cognitive decline in patients with mild cognitive impairment (MCI) and early dementia,
including Alzheimer’s disease. He shares clinical case studies, mechanistic insights, and exciting future directions for
this emerging treatment approach.

What You’ll Learn

• Evidence-Based Improvements: Case studies showing cognitive gains in MCI and early Alzheimer’s after
  a structured HBOT protocol, with real-world patient metrics detailing memory and executive function enhancements.
• Mechanisms at Work: HBOT boosts cerebral blood flow, reduces neuroinflammation, guards against
  oxidative stress, and promotes angiogenesis and neurogenesis.
• Protocol Blueprint: Typically 1.5–2.0 ATA for 60–90 minutes per session, often daily for 40–60 cycles,
  with progress tracked via MoCA, MMSE, and advanced brain imaging.
• Dr. Harch’s Perspective: Dementia may have reversible elements when microvascular ischemia and
  inflammation are addressed; calls for broader clinical trials and institutional support.

Why It Matters

Dementia cases are projected to rise globally, and innovative treatments are urgently needed. HBOT, already FDA-approved
for specific conditions, shows promising off-label potential for brain repair. Early, guided intervention can halt or
even reverse cognitive decline.

For Healthcare Providers & Caregivers

• Providers: Learn how to integrate HBOT into neurotherapeutic protocols and design clinical trials.
• Caregivers & Patients: Understand signs that HBOT may be viable and advocate for access or study enrollment.

Call to Action

Curious whether HBOT could make a difference for you or a loved one? Watch the full talk above to hear directly from Dr. Harch.
Review referenced studies, connect with certified HBOT clinics, and share your thoughts or experiences in the comments.
Together, we can build a community informed on brain health innovations.